186 related articles for article (PubMed ID: 22258869)
21. Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study.
Bower M; Metzger T; Robbins K; Tomalty D; Válek V; Boudný J; Andrasina T; Tatum C; Martin RC
HPB (Oxford); 2010 Feb; 12(1):31-6. PubMed ID: 20495642
[TBL] [Abstract][Full Text] [Related]
22. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases.
Ychou M; Viret F; Kramar A; Desseigne F; Mitry E; Guimbaud R; Delpero JR; Rivoire M; Quénet F; Portier G; Nordlinger B
Cancer Chemother Pharmacol; 2008 Jul; 62(2):195-201. PubMed ID: 17901955
[TBL] [Abstract][Full Text] [Related]
23. Routine Preoperative Liver-specific Magnetic Resonance Imaging Does Not Exclude the Necessity of Contrast-enhanced Intraoperative Ultrasound in Hepatic Resection for Colorectal Liver Metastasis.
Arita J; Ono Y; Takahashi M; Inoue Y; Takahashi Y; Matsueda K; Saiura A
Ann Surg; 2015 Dec; 262(6):1086-91. PubMed ID: 26010441
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of resection for colorectal cancer hepatic metastases stratified by evolving eras of treatment.
Chan KM; Chiang JM; Lee CF; Yu MC; Lee WC; Chen JS; Wang JY
World J Surg Oncol; 2011 Dec; 9():174. PubMed ID: 22208884
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes.
Sahajpal A; Vollmer CM; Dixon E; Chan EK; Wei A; Cattral MS; Taylor BR; Grant DR; Greig PD; Gallinger S
J Surg Oncol; 2007 Jan; 95(1):22-7. PubMed ID: 17066435
[TBL] [Abstract][Full Text] [Related]
26. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases.
Scoggins CR; Campbell ML; Landry CS; Slomiany BA; Woodall CE; McMasters KM; Martin RC
Ann Surg Oncol; 2009 Jan; 16(1):35-41. PubMed ID: 18987915
[TBL] [Abstract][Full Text] [Related]
27. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
Primrose J; Falk S; Finch-Jones M; Valle J; O'Reilly D; Siriwardena A; Hornbuckle J; Peterson M; Rees M; Iveson T; Hickish T; Butler R; Stanton L; Dixon E; Little L; Bowers M; Pugh S; Garden OJ; Cunningham D; Maughan T; Bridgewater J
Lancet Oncol; 2014 May; 15(6):601-11. PubMed ID: 24717919
[TBL] [Abstract][Full Text] [Related]
28. Liver resection rate following downsizing chemotherapy with cetuximab in metastatic colorectal cancer: UK retrospective observational study.
Malik H; Khan AZ; Berry DP; Cameron IC; Pope I; Sherlock D; Helmy S; Byrne B; Thompson M; Pulfer A; Davidson B
Eur J Surg Oncol; 2015 Apr; 41(4):499-505. PubMed ID: 25703078
[TBL] [Abstract][Full Text] [Related]
29. Effect of preoperative chemotherapy on liver resection for colorectal liver metastases.
Mehta NN; Ravikumar R; Coldham CA; Buckels JA; Hubscher SG; Bramhall SR; Wigmore SJ; Mayer AD; Mirza DF
Eur J Surg Oncol; 2008 Jul; 34(7):782-6. PubMed ID: 18160247
[TBL] [Abstract][Full Text] [Related]
30. Complete pathological response (ypT0N0M0) after preoperative chemotherapy alone for stage IV rectal cancer.
Naiken SP; Toso C; Rubbia-Brandt L; Thomopoulos T; Roth A; Mentha G; Morel P; Gervaz P
BMC Surg; 2014 Jan; 14():4. PubMed ID: 24438090
[TBL] [Abstract][Full Text] [Related]
31. Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer.
Bouchahda M; Boige V; Smith D; Karaboué A; Ducreux M; Hebbar M; Lepère C; Focan C; Guimbaud R; Innominato P; Awad S; Carvalho C; Tumolo S; Truant S; De Baere T; Castaing D; Rougier P; Morère JF; Taieb J; Adam R; Lévi F;
Eur J Cancer; 2016 Nov; 68():163-172. PubMed ID: 27768923
[TBL] [Abstract][Full Text] [Related]
32. A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases.
Chun YJ; Kim SG; Lee KW; Cho SH; Kim TW; Baek JY; Park YS; Hong S; Chu CW; Beom SH; Jung M; Shin SJ; Ahn JB
Clin Colorectal Cancer; 2020 Sep; 19(3):e140-e150. PubMed ID: 32402681
[TBL] [Abstract][Full Text] [Related]
33. Nomogram predicted disease free survival for colorectal liver metastasis patients with preoperative chemotherapy followed by hepatic resection.
Liu W; Wang K; Han Y; Liang JY; Li YH; Xing BC
Eur J Surg Oncol; 2019 Nov; 45(11):2070-2077. PubMed ID: 31279595
[TBL] [Abstract][Full Text] [Related]
34. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.
Ye LC; Liu TS; Ren L; Wei Y; Zhu DX; Zai SY; Ye QH; Yu Y; Xu B; Qin XY; Xu J
J Clin Oncol; 2013 Jun; 31(16):1931-8. PubMed ID: 23569301
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes.
DʼAngelica MI; Correa-Gallego C; Paty PB; Cercek A; Gewirtz AN; Chou JF; Capanu M; Kingham TP; Fong Y; DeMatteo RP; Allen PJ; Jarnagin WR; Kemeny N
Ann Surg; 2015 Feb; 261(2):353-60. PubMed ID: 24646562
[TBL] [Abstract][Full Text] [Related]
36. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases.
Masi G; Loupakis F; Pollina L; Vasile E; Cupini S; Ricci S; Brunetti IM; Ferraldeschi R; Naso G; Filipponi F; Pietrabissa A; Goletti O; Baldi G; Fornaro L; Andreuccetti M; Falcone A
Ann Surg; 2009 Mar; 249(3):420-5. PubMed ID: 19247029
[TBL] [Abstract][Full Text] [Related]
37. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases.
Shindoh J; Loyer EM; Kopetz S; Boonsirikamchai P; Maru DM; Chun YS; Zimmitti G; Curley SA; Charnsangavej C; Aloia TA; Vauthey JN
J Clin Oncol; 2012 Dec; 30(36):4566-72. PubMed ID: 23150701
[TBL] [Abstract][Full Text] [Related]
38. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy.
Auer RC; White RR; Kemeny NE; Schwartz LH; Shia J; Blumgart LH; Dematteo RP; Fong Y; Jarnagin WR; D'Angelica MI
Cancer; 2010 Mar; 116(6):1502-9. PubMed ID: 20120032
[TBL] [Abstract][Full Text] [Related]
39. Radiofrequency ablation of colorectal liver metastases downstaged by chemotherapy.
Knudsen AR; Kannerup AS; Mortensen FV; Nielsen DT
Acta Radiol; 2009 Sep; 50(7):716-21. PubMed ID: 19488894
[TBL] [Abstract][Full Text] [Related]
40. Management of disappearing colorectal liver metastases.
Kuhlmann K; van Hilst J; Fisher S; Poston G
Eur J Surg Oncol; 2016 Dec; 42(12):1798-1805. PubMed ID: 27260846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
